psychedelic-assisted psychotherapy
The company says it will begin full commercial deployment of iSTRYM in the first quarter of 2022.
TRIPP PsyAssist will provide protocols and anxiety-easing support to patients undergoing ketamine-assisted therapy.
The platform works to empower patients to be more active in their care journey – and also creates a database of clinical practices and protocols for the psychedelic research community.